GUB06‐046, a novel secretin/glucagon‐like peptide 1 co‐agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice

Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight‐lowering effects of bariatric surgery involve stimulated secretion of appetite‐regulating gut hormones, including glucagon‐like peptide 1. We here report that intestinal expression of secretin is markedly upregulated in a rat model of Roux‐en‐Y gastric bypass, suggesting an additional role of secretin in the beneficial metabolic effects of Roux‐en‐Y gastric bypass. We therefore developed novel secretin‐based peptide co‐agonists and identified a lead compound, GUB06‐046, that exhibited potent agonism of both the secretin receptor and glucagon‐like peptide 1 receptor. Semi‐acute administration of GUB06‐046 to lean mice significantly decreased cumulative food intake and improved glucose tolerance. Chronic administration of GUB06‐046 to diabetic db/db mice for 8 weeks improved glycemic control, as indicated by a 39% decrease in fasting blood glucose and 1.6% reduction of plasma HbA1c levels. Stereological analysis of db/db mice pancreata revealed a 78% increase in beta‐cell mass after GUB06‐046 treatment, with no impact on exocrine pancreas mass or pancreatic duct epithelial mass. The data demonstrate beneficial effects of GUB06‐046 on appetite regulation, glucose homeostasis, and beta‐cell mass in db/db mice, without proliferative effects on the exocrine pancreas and the pancreatic duct epithelium. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.

[1]  J. Jelsing,et al.  A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents , 2015, PloS one.

[2]  L. Scott.  Liraglutide: A Review of Its Use in the Management of Obesity , 2015, Drugs.

[3]  Xiaohua Han,et al.  Effects of secretin on neuronal activity and feeding behavior in central amygdala of rats , 2015, Peptides.

[4]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[5]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[6]  R. Sekar,et al.  Secretin receptor‐knockout mice are resistant to high‐fat diet‐induced obesity and exhibit impaired intestinal lipid absorption , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  S. Hansen.  Update for BayesApp: a web site for analysis of small‐angle scattering data , 2014 .

[8]  A. Astrup,et al.  Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. , 2014, American journal of physiology. Endocrinology and metabolism.

[9]  J. Jelsing,et al.  Characterisation of Age-Dependent Beta Cell Dynamics in the Male db/db Mice , 2013, PloS one.

[10]  A. Pocai,et al.  A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. , 2013, Bioorganic & medicinal chemistry.

[11]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[12]  N. Irwin,et al.  A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice* , 2013, The Journal of Biological Chemistry.

[13]  R. Ryder.  The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[14]  A. Evers,et al.  Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. , 2013, Bioorganic & medicinal chemistry letters.

[15]  J. Jelsing,et al.  Hypertrophy Dependent Doubling of L-Cells in Roux-en-Y Gastric Bypass Operated Rats , 2013, PloS one.

[16]  R. Elashoff,et al.  A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.

[17]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[18]  A. E. Jensen,et al.  The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. , 2012, American journal of physiology. Endocrinology and metabolism.

[19]  Steen H. Hansen,et al.  BayesApp: a web site for indirect transformation of small-angle scattering data , 2012 .

[20]  M. Tschöp,et al.  Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity , 2012, Diabetes.

[21]  S. Dry,et al.  Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model , 2012, Diabetes.

[22]  S. Gortmaker,et al.  Health and economic burden of the projected obesity trends in the USA and the UK , 2011, The Lancet.

[23]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[24]  L. Miller,et al.  Importance of each residue within secretin for receptor binding and biological activity. , 2011, Biochemistry.

[25]  N. Tsomaia,et al.  Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[26]  Adam Round,et al.  New beamline dedicated to solution scattering from biological macromolecules at the ESRF , 2010 .

[27]  M. Culler,et al.  Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. , 2010, Endocrinology.

[28]  J. Mikkelsen,et al.  Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat , 2010, Neuropsychopharmacology.

[29]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[30]  C. Beglinger,et al.  Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy: A Prospective Randomized Trial , 2009, Annals of surgery.

[31]  Michael E. Lassman,et al.  Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.

[32]  M. Jensen,et al.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. , 2009, The American journal of medicine.

[33]  J. Teixeira,et al.  Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[34]  L. B. Knudsen,et al.  Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. , 2007, Journal of medicinal chemistry.

[35]  S. Bloom,et al.  Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.

[36]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[37]  S. Bonner-Weir,et al.  GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts , 2006 .

[38]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[39]  Mohammad A Ghatei,et al.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.

[40]  W. Chey,et al.  Secretin, 100 years later , 2003, Journal of gastroenterology.

[41]  B. Pakkenberg,et al.  Increased islet volume but unchanged islet number in ob/ob mice. , 2003, Diabetes.

[42]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[43]  G. Klöppel,et al.  Pathology of Acute and Chronic Pancreatitis , 1993, Pancreas.

[44]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[45]  Wei Zhang,et al.  A Meta-Analysis of Short-Term Outcomes of Patients with Type 2 Diabetes Mellitus and BMI ≤35 kg/m2 Undergoing Roux-en-Y Gastric Bypass , 2014, World Journal of Surgery.

[46]  M. Erion,et al.  Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents , 2012, Biopolymers.

[47]  B. Chow,et al.  Central and Peripheral Administration of Secretin Inhibits Food Intake in Mice through the Activation of the Melanocortin System , 2011, Neuropsychopharmacology.

[48]  S. Gortmaker,et al.  Obesity 2 Health and economic burden of the projected obesity trends in the USA and the UK , 2011 .

[49]  B. Chow,et al.  Multiple actions of secretin in the human body. , 2008, International review of cytology.

[50]  S. Bonner-Weir,et al.  GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. , 2006, Diabetes research and clinical practice.

[51]  M. Bessler,et al.  Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. , 2005, The Journal of clinical endocrinology and metabolism.

[52]  J. Polak,et al.  Immunofluorescent localization of secretin and enteroglucagon in human intestinal mucosa. , 1971, Scandinavian journal of gastroenterology.

[53]  W. H. Hattie.  Mechanism of Pancreatic Secretion. , 1926, Canadian Medical Association journal.